- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Rajesh Rajpal on Eye Health Implications of Visual Needs in Younger Populations
Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses how greater visual needs are contributing to adverse eye health in younger populations.
With visual needs rising substantially in recent years, eye conditions such as cataract have been shown to be more impactful at an earlier age, said Raj Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision.
Transcript
Can you speak on the growing prevalence of cataracts in younger populations?
I wouldn't say that they're necessarily being noticed at an earlier age, I think it's just more impactful at an earlier age because of our visual needs. So, certainly all of the types of conditions we've talked about that can contribute to cataracts at an earlier age, we still need to watch for.
Again, whether they're medical causes, trauma, or medications as examples, but because of our greater visual needs, we are finding that we're doing cataract surgery at an earlier age because patients’ vision is impacting their life and that's when we primarily choose to perform cataract surgery.
It’s when a patient's vision is impacting their daily functioning, and therefore then we can, by cataract surgery, remove the natural lens, the cloudy lens of the eye, and implant an intraocular lens that makes up for the power. And then we have different options in how we select those intraocular lenses and what we do in cataract surgery.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
